Probiotic Therapy With VSL#3® in Patients With NAFLD: A Randomized Clinical Trial

Derosa, Giuseppe; Guasti, Luigina; D’Angelo, Angela; Martinotti, Chiara; Valentino, Maria Chiara; Matteo, S. Di; Bruno, Giacomo Matteo; Maresca, Andrea Maria; Gaudio, Giovanni; Maffioli, Pamela

doi:10.3389/fnut.2022.846873

Cited by 26 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a randomized controlled study revealed that patients with NAFLD treated daily with Lactobacillus and Bifidobacterium species showed decreased levels of ALT and γGT, decreased counts of CD4+ T-cells and CD8+ T-cells, and improved HS fibrosis (87). Chong et al (88) and Derosa et al (89) found that NAFLD patients treated with VSL#3 R had a decreased AST/ALT ratio and hs-CRP level and improved IR and endothelial dysfunction. In addition, patients with NAFLD supplemented with metformin and probiotics showed improved serum AST and ALT levels and ultrasound grading of NASH (90).…”

Section: Craven Et Al (1)mentioning

confidence: 99%

Gut microbiota–mitochondrial inter-talk in non-alcoholic fatty liver disease

et al. 2022

View full text Add to dashboard Cite

The increasing prevalence of non-alcoholic fatty liver disease (NAFLD), which is a progressive disease, has exerted huge a healthcare burden worldwide. New investigations have suggested that the gut microbiota closely participates in the progression of NAFLD through the gut–liver axis or gut–brain–liver axis. The composition of the microbiota can be altered by multiple factors, primarily dietary style, nutritional supplements, or exercise. Recent evidence has revealed that gut microbiota is involved in mitochondrial biogenesis and energy metabolism in the liver by regulating crucial transcription factors, enzymes, or genes. Moreover, microbiota metabolites can also affect mitochondrial oxidative stress function and swallow formation, subsequently controlling the inflammatory response and regulating the levels of inflammatory cytokines, which are the predominant regulators of NAFLD. This review focuses on the changes in the composition of the gut microbiota and metabolites as well as the cross-talk between gut microbiota and mitochondrial function. We thus aim to comprehensively explore the potential mechanisms of gut microbiota in NAFLD and potential therapeutic strategies targeting NAFLD management.

show abstract

Section: Craven Et Al (1)mentioning

confidence: 99%

Gut microbiota–mitochondrial inter-talk in non-alcoholic fatty liver disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…97,98 A randomized trial including 60 NAFLD patients reported a significant reduction in triglycerides, transaminases, and gamma-glutamyltransferase, but no change in fasting plasma glucose, total cholesterol, low-density lipoprotein-cholesterol and highdensity lipoprotein-cholesterol with VSL#3 compared with controls. 99 The evidence suggests probiotics and prebiotics have a possible benefit in NAFLD, high-quality studies are still limited.…”

Section: Role Of the Intestinal Microbial Barrier In Nafld Developmentmentioning

confidence: 99%

Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease

Liu¹,

Yin²,

Gao³

et al. 2022

J Clin Transl Hepatol

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. The mechanisms involved in NAFLD onset are complicated and multifactorial. Recent literature has indicated that altered intestinal barrier function is related to the occurrence and progression of liver disease. The intestinal barrier is important for absorbing nutrients and electrolytes and for defending against toxins and antigens in the enteric environment. Major mechanisms by which the intestinal barrier influences the development of NAFLD involve the altered epithelial layer, decreased intracellular junction integrity, and increased intestinal barrier permeability. Increased intestinal permeability leads to luminal dysbiosis and allows the translocation of pathogenic bacteria and metabolites into the liver, inducing inflammation, immune response, and hepatocyte injury in NAFLD. Although research has been directed to NAFLD in recent decades, the pathophysiological changes in NAFLD initiation and progression are still not completely understood, and the therapeutic targets remain limited. A deeper understanding on the correlation between NAFLD pathogenesis and intestinal barrier regulation must be attained. Therefore, in this review, the components of the intestinal barrier and their respective functions and disruptions during the progression of NAFLD are discussed.

show abstract

“…A randomized, double-blind, placebo-controlled clinical trial showed that multistrain probiotic supplementation can decrease insulin, insulin resistance, TNFα, and IL-6 in patients with NAFLD [ 178 ]; further, in the same line, treatment with Lactobacillus bulgaricus and Streptococcus thermophilus can decrease ALT and AST activity, and gamma glutamyl transferase (GGT) levels in NAFLD patients [ 179 ]. Another randomized, double-blind, placebo-controlled clinical trial reports that administration of VSL#3 decreased triglycerides and high-sensitivity C-reactive protein levels, as well as transaminases and GGT activity [ 180 ]. Interestingly, Shavakhi et al demonstrated that treatment with Metformin plus Protexin ( L. acidophilus , L. casei , L. rhamnosus , L. bulgaricus , B. breve , B. longum , Streptococcus thermophilus ) decreases ALT and AST activity, better than Metformin alone in patients with NASH [ 181 ].…”

Section: Probioticsmentioning

confidence: 99%

Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention

Campagnoli

Marchesi

Vairetti

et al. 2022

Cells

View full text Add to dashboard Cite

Human aging, a natural process characterized by structural and physiological changes, leads to alterations of homeostatic mechanisms, decline of biological functions, and subsequently, the organism becomes vulnerable to external stress or damage. In fact, the elderly population is prone to develop diseases due to deterioration of physiological and biological systems. With aging, the production of reactive oxygen species (ROS) increases, and this causes lipid, protein, and DNA damage, leading to cellular dysfunction and altered cellular processes. Indeed, oxidative stress plays a key role in the pathogenesis of several chronic disorders, including hepatic diseases, such as non-alcoholic fatty liver disease (NAFLD). NAFLD, the most common liver disorder in the Western world, is characterized by intrahepatic lipid accumulation; is highly prevalent in the aging population; and is closely associated with obesity, insulin resistance, hypertension, and dyslipidemia. Among the risk factors involved in the pathogenesis of NAFLD, the dysbiotic gut microbiota plays an essential role, leading to low-grade chronic inflammation, oxidative stress, and production of various toxic metabolites. The intestinal microbiota is a dynamic ecosystem of microbes involved in the maintenance of physiological homeostasis; the alteration of its composition and function, during aging, is implicated in different liver diseases. Therefore, gut microbiota restoration might be a complementary approach for treating NAFLD. The administration of probiotics, which can relieve oxidative stress and elicit several anti-aging properties, could be a strategy to modify the composition and restore a healthy gut microbiota. Indeed, probiotics could represent a valid supplement to prevent and/or help treating some diseases, such as NAFLD, thus improving the already available pharmacological intervention. Moreover, in aging, intervention of prebiotics and fecal microbiota transplantation, as well as probiotics, will provide novel therapeutic approaches. However, the relevant research is limited, and several scientific research works need to be done in the near future to confirm their efficacy.

show abstract

Probiotic Therapy With VSL#3® in Patients With NAFLD: A Randomized Clinical Trial

Cited by 26 publications

References 33 publications

Gut microbiota–mitochondrial inter-talk in non-alcoholic fatty liver disease

Gut microbiota–mitochondrial inter-talk in non-alcoholic fatty liver disease

Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease

Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention

Contact Info

Product

Resources

About